{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:05:23Z","timestamp":1791288323359,"version":"4.3.0"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,6,28]],"date-time":"2004-06-28T00:00:00Z","timestamp":1088380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine. The medical records of 116 patients with hepatobiliary carcinoma who were treated at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between July 1998 and March 1999 were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 63 patients were treated with capecitabine (37 with HCC, 18 with CCA, 8 with GBC). Capecitabine 1000 mg\/m<jats:sup>2<\/jats:sup> was administered twice daily for 14 days. Treatment was repeated every 21 days. Each patient received 1\u201315 treatment cycles. Nine patients (14%)\u201411% of patients with HCC, 6% of patients with CCA, and 50% of patients with GBC\u2014had either a complete response (CR) or a partial response. A CR was radiologically confirmed in one patient with HCC and in two patients with GBC. The median survival times were 10.1 months (95% confidence interval [CI], 4.5\u201315.7 months) for patients with HCC, 8.1 months (95% CI, 7.4\u20138.9 months) for patients with CCA, and 9.9 months (95% CI, 4.4\u201315.4 months) for patients with GBC. The most common toxicity was hand\u2010foot syndrome (37%). Grade 3 thrombocytopenia occurred in 8% of patients with HCC. No other significant toxicities were observed. For all patients, response to treatment was positively correlated with survival and decline in tumor markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Capecitabine was found to be safe for patients with hepatobiliary carcinoma, including those with cirrhosis. The antitumor activity of single\u2010agent capecitabine was most pronounced in patients with GBC, was modest in patients with HCC, and was poor in patients with CCA. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20368","type":"journal-article","created":{"date-parts":[[2004,6,28]],"date-time":"2004-06-28T12:00:51Z","timestamp":1088424051000},"page":"578-586","source":"Crossref","is-referenced-by-count":162,"title":["Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma"],"prefix":"10.1002","volume":"101","author":[{"given":"Yehuda Z.","family":"Patt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Aguayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Nicolas","family":"Vauthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isac I.","family":"Schnirer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chusilp","family":"Charnsangavej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,6,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401001"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.21.3227"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.1998.00865.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90352-8"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00516.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830115)51:2<206::AID-CNCR2820510206>3.0.CO;2-P"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199904000-00024"},{"key":"e_1_2_5_10_2","first-page":"1676","article-title":"Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma","volume":"5","author":"Leung TW","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70175-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25087"},{"key":"e_1_2_5_13_2","first-page":"51","article-title":"Cholangiocarcinoma and the role of radiation and chemotherapy","volume":"48","author":"Price P","year":"2001","journal-title":"Hepatogastroenterology."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70161-6"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(05)70208-5"},{"key":"e_1_2_5_16_2","first-page":"125","article-title":"Cholangiocarcinoma","volume":"12","author":"Torok N","year":"2001","journal-title":"Semin Gastrointest Dis."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004230000189"},{"key":"e_1_2_5_18_2","first-page":"3375","article-title":"Phase II trial of cisplatin, interferon \u03b1\u20102b, doxorubicin, and 5\u2010fluorouracil for biliary tract cancer","volume":"7","author":"Patt YZ","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00682-5"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050043"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00058-6"},{"key":"e_1_2_5_22_2","first-page":"447","article-title":"Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine","volume":"26","author":"Saeki T","year":"1999","journal-title":"Gan To Kagaku Ryoho."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6"},{"key":"e_1_2_5_24_2","first-page":"1696","article-title":"Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites","volume":"5","author":"Twelves C","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.087"},{"key":"e_1_2_5_27_2","volume-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.1-2.203"},{"key":"e_1_2_5_30_2","volume-title":"Statistical methods for survival analysis","author":"Lee ET","year":"1992"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280322"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001201)89:11<2266::AID-CNCR15>3.0.CO;2-0"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27219"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2311"},{"key":"e_1_2_5_35_2","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol\/Taxotere in human cancer xenografts","volume":"4","author":"Sawada N","year":"1998","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11910"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.103"},{"issue":"12","key":"e_1_2_5_38_2","first-page":"1035","article-title":"Phase II study of thalidomide for the treatment of hepatocellular carcinoma","volume":"14","author":"Patt YZ","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_39_2","first-page":"209","article-title":"Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon\u2010alpha","volume":"117","author":"Sgonc R","year":"1998","journal-title":"Int Arch Allergy Immunol."},{"key":"e_1_2_5_40_2","first-page":"808","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon\u2010alpha administration","volume":"58","author":"Dinney CP","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_5_41_2","first-page":"685","article-title":"Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts","volume":"58","author":"Ishikawa T","year":"1998","journal-title":"Cancer Res."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20368","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:11:44Z","timestamp":1760260304000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,28]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1002\/cncr.20368"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20368","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,28]]}}}